Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients

Journal of Human Hypertension

Volumn 22, Issue 5, 2008, Pages 358-365

  Vlek, A L M ^a   van der Graaf, Y ^a   Spiering, W ^a   Visseren, F L J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RECURRENCE; SURVIVAL RATE;

EID: 42449103122     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2008.5     Document Type: Article

References (36)

1. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality; a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903-1913.
2. National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333-1445.
3. Zavaroni I, Mazza S, Dall'Aglio E, Gasparini P, Passeri M, Reaven GM. Prevalence of hyperinsulinaemia in patients with high blood pressure. J Intern Med 1992; 231: 235-240.
4. Lind L, Berne C, Lithell H. Prevalence of insulin resistance in essential-hypertension. J Hypertens 1995; 13: 1457-1462.
5. Ishizaka. N, Ishizaka Y, Toda E, Hashimoto H, Nagai R, Yamakado M. Hypertension is the most common component of metabolic syndrome and the greatest contributor to carotid arteriosclerosis in apparently healthy Japanese individuals. Hypertens Res 2005; 28: 27-34.
6. Almgren T, Persson B, Withelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension - a prospective cohort study over three decades. J Intern Med 2005; 257: 496-502.
7. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 200; 365: 1415-1428.
9. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
10. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005; 112: 3066-3072.
11. Gorter PM, Olijhoek JK, van der Graaf Y, Algra A, Rabelink TJ, Visseren FL. Prevalence of the metabolic syndrome in patients with coronary heart disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. Atherosclerosis 2004; 173: 363-369.
12. Espinola-Klein C, Rupprecht HJ, Bickel C, Post F, Genth-Zotz S, Lackner K et al. Impact of metabolic syndrome on atherosclerotic burden and cardiovascular prognosis. Am J Cardiol 2007; 99: 1623-1628.
13. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994. Diabetes Care 1998; 21 518-524.
14. Hanson RL, Imperatore G, Bennett PH, Knowler WC. Components of the 'metabolic syndrome' and incidence of type 2 diabetes. Diabetes 2002; 51: 3120-3127.
15. Laaksonen DE, Lakka HM, Niskanen LK, Kaplan GA, Salonen JT, Lakka TA. Metabolic syndrome and development of diabetes mellitus: Application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study. Am J Epidemiol 2002; 156: 1070-1077.
16. Resnick HE, Jones K, Ruotolo G, Jain AK, Henderson J, Lu W et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: The Strong Heart Study. Diabetes Care 2003; 26: 861-867.
17. Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002; 25: 1790-1794.
18. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM et al Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of scotland coronary prevention study. Circulation 2003; 108: 414-419.
19. Girman CJ, Rhodes T, Mercuri M, Pyorala K, Kjekshus J, Pedersen TR et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004; 93: 136-141.
20. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR et al Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
21. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709-2716.
22. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: A population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2004; 164: 1422-1426.
23. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004; 25: 342-348.
24. Nigam A, Bourassa MG, Fortier A, Guertin MC, Tardif JC. The metabolic syndrome and its components and the long-term risk of death in patients with coronary heart disease. Am Heart J 2006; 151: 514-521.
25. Leoncini G, Ratto E, Viazzi F, Vaccaro V, Parodi D, Parodi A et al Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 2005; 257: 454-460.
26. Mule G, Nardi E, Cottone S, Cusimano P, Volpe V, Piazza G et al. Influence of metabolic syndrome on hypertension-related target organ damage. J Intern Med 2005; 257: 503-513.
27. Schillaci G, Pirro M, Vaudo G, Mannarino MR, Savarese G, Pucci G et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 2005; 45: 1078-1082.
28. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43: 1817-1822.
29. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E et al Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991-1998.
30. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: Analysis of the treating to new targets study. Lancet 2006; 368: 919-928.
31. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: Rationale and design. Eur J Epidemiol 1999; 15: 773-781.
32. Stern MP, Williams K, Hunt KJ. Impact of diabetes/metabolic syndrome in patients with established cardiovascular disease. Atheroscler Suppl 2005; 6: 3-6.
33. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among III NHANES participants age 50 years and older. Diabetes 2003; 52: 1210-1214.
34. Levantesi G, Macchia A, Marfisi R, Franzosi MG, Maggioni AP, Nicolosi GL et al. Metabolic syndrome and risk of cardiovascular events after myocardial infarction. J Am Coll Cardiol 2005; 46: 277-283.
35. Najarian RM, Sullivan LM, Kannel WB, Wilson PW, D'Agostino RB, Wolf PA. Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: The Framingham Offspring Study. Arch Intern Med 2006; 166: 106-111.
36. Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990; 263: 2893-2898.